Statin policy and target populations: evidence-based or evidence-biased?

被引：2

作者：

Durrington, P ^{[1
]}

机构：

[1] Univ Manchester, Manchester Royal Infirm, Dept Med, Manchester M13 9WL, Lancs, England

来源：

CURRENT OPINION IN LIPIDOLOGY | 2004年 / 15卷 / 04期

关键词：

D O I：

10.1097/01.mol.0000137223.61901.a9

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：381 / 386

页数：6

共 36 条

[1] CARDIOVASCULAR-DISEASE RISK PROFILES [J].

ANDERSON, KM ;

ODELL, PM ;

WILSON, PWF ;

KANNEL, WB .

AMERICAN HEART JOURNAL, 1991, 121 (01) :293-298

[2] Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].

Cannon, CP ;

Braunwald, E ;

McCabe, CH ;

Rader, DJ ;

Rouleau, JL ;

Belder, R ;

Joyal, SV ;

Hill, KA ;

Pfeffer, MA ;

Skene, AM .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504

[3] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].

Cleeman, JI ;

Grundy, SM ;

Becker, D ;

Clark, LT ;

Cooper, RS ;

Denke, MA ;

Howard, WJ ;

Hunninghake, DB ;

Illingworth, DR ;

Luepker, RV ;

McBride, P ;

McKenney, JM ;

Pasternak, RC ;

Stone, NJ ;

Van Horn, L ;

Brewer, HB ;

Ernst, ND ;

Gordon, D ;

Levy, D ;

Rifkind, B ;

Rossouw, JE ;

Savage, P ;

Haffner, SM ;

Orloff, DG ;

Proschan, MA ;

Schwartz, JS ;

Sempos, CT ;

Shero, ST ;

Murray, EZ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497

[4] BLOOD-PRESSURE, ANTIHYPERTENSIVE DRUG-TREATMENT AND THE RISKS OF STROKE AND OF CORONARY HEART-DISEASE [J].

COLLINS, R ;

MACMAHON, S .

BRITISH MEDICAL BULLETIN, 1994, 50 (02) :272-298

[5]

Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3

[6]

Collins R, 2003, LANCET, V361, P2005

[7] European guidelines on cardiovascular disease prevention in clinical practice -: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts) [J].

De Backer, G ;

Ambrosioni, E ;

Borch-Johnsen, K ;

Brotons, C ;

Cifkova, R ;

Dallongeville, J ;

Ebrahim, S ;

Faergeman, O ;

Graham, I ;

Mancia, G ;

Cats, VM ;

Orth-Gomér, K ;

Perk, J ;

Pyörälä, I ;

Rodicio, JL ;

Sans, S ;

Sansoy, V ;

Sechtem, U ;

Silber, S ;

Thomsen, T ;

Wood, D .

ATHEROSCLEROSIS, 2003, 171 (01) :145-155

[8]

*DEP HLTH, 2000, NAT HLTH SERV FRAM C

[9] Dyslipidaemia [J].

Durrington, P .

LANCET, 2003, 362 (9385) :717-731

[10] Indications for cholesterol-lowering medication: comparison of risk-assessment methods [J].

Durrington, PN ;

Prais, H ;

Bhatnagar, D ;

France, M ;

Crowley, V ;

Khan, J ;

Morgan, J .

LANCET, 1999, 353 (9149) :278-281

← 1 2 3 4 →